Abivax raises $920M to launch drug solo in the US without seeking a buyer

French biotech company Abivax has raised $920 million in its latest funding round, giving it enough cash to finance operations through 2029. With this capital, the company no longer needs to seek a buyer and will instead independently launch its drug in the United States. The CEO announced the plans in an interview with CNBC.